Breathe BioMedical Inc. (BRTH)

Breathe BioMedical was planning to go public, but the IPO was withdrawn on Oct 28, 2024.
IPO Price Range
$4.00 - $6.00
Shares Offered
2,625,000
Deal Size
$13.13M
Chart not available yet
Data will show when the stock starts trading.
Market Cap 57.36M
Revenue (ttm) n/a
Net Income (ttm) -7.64M
Shares Out 11.47M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About BRTH

Breathe BioMedical is a medical technology company focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breathe BioMedical is in the development stage of our Breast Cancer Breath Test. Over the next two years we have verification and validation studies planned for the components and the Breast Cancer Breath Test, as well as a large multi-center clinical study planned to evaluate the safety and efficacy of the Breast Cancer Breath Test... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2005
Employees 26
Stock Exchange NASDAQ
Ticker Symbol BRTH
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

News

Canadian diagnostics developer Breathe BioMedical files for a $12 million dual listing in the US and Canada

Breathe BioMedical, a Canadian medical technology company developing a breath test for breast cancer...

7 months ago - Renaissance Capital

Breathe BioMedical IPO Registration Document (F-1)

Breathe BioMedical has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC